Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rosalba Mansi

Showing results (31-40 of 54) with videos related to

Pageof 6
Sort By:
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 23, 2014
N-terminal modifications improve the receptor affinity and pharmacokinetics of radiolabeled peptidic gastrin-releasing peptide receptor antagonists: examples of 68Ga- and 64Cu-labeled peptides for PET imagingEleni Gourni, Rosalba Mansi, Mazen Jamous, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 15, 2011
Bombesin antagonist-based radioligands for translational nuclear imaging of gastrin-releasing peptide receptor-positive tumorsKeelara Abiraj, Rosalba Mansi, Maria-Luisa Tamma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2009
Evaluation of a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-conjugated bombesin-based radioantagonist for the labeling with single-photon emission computed tomography, positron emission tomography, and therapeutic radionuclidesRosalba Mansi, Xuejuan Wang, Flavio Forrer, et al.
Journal of Medicinal Chemistry|December 5, 2014
Evaluation of three different families of bombesin receptor radioantagonists for targeted imaging and therapy of gastrin releasing peptide receptor (GRP-R) positive tumorsRosalba Mansi, Keelara Abiraj, Xuejuan Wang, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 30, 2016
Approaches to Improve the Pharmacokinetics of Radiolabeled Glucagon-Like Peptide-1 Receptor Ligands Using Antagonistic TracersSvetlana N Rylova, Beatrice Waser, Luigi Del Pozzo, et al.
EJNMMI Research|February 22, 2016
Pre-clinical evaluation of eight DOTA coupled gastrin-releasing peptide receptor (GRP-R) ligands for in vivo targeting of receptor-expressing tumorsAntonella Accardo, Filippo Galli, Rosalba Mansi, et al.
EJNMMI Radiopharmacy and Chemistry|August 21, 2025
Enhanced contrast in FAP-targeting PET imaging with <sup>61</sup>Cu-labeled FAP inhibitors: development and preclinical evaluation of novel [<sup>61</sup>Cu]Cu-Kalios PET radioligandsJacopo Millul, Tais Basaco Bernabeu, Raghuvir H Gaonkar, et al.
Bioconjugate Chemistry|May 15, 2015
Stereochemistry of amino acid spacers determines the pharmacokinetics of (111)In-DOTA-minigastrin analogues for targeting the CCK2/gastrin receptorPetra Kolenc Peitl, MariaLuisa Tamma, Marko Kroselj, et al.
EJNMMI Research|February 18, 2014
Synergism of peptide receptor-targeted Auger electron radiation therapy with anti-angiogenic compounds in a mouse model of neuroendocrine tumorsAndreas Wicki, Damian Wild, Vincent Prêtre, et al.
Journal of Translational Medicine|September 7, 2023
CUDC-907, a dual PI3K/histone deacetylase inhibitor, increases meta-iodobenzylguanidine uptake (<sup>123/131</sup>I-mIBG) in vitro and in vivo: a promising candidate for advancing theranostics in neuroendocrine tumorsJoana Grand-Guillaume, Rosalba Mansi, Raghuvir H Gaonkar, et al.
Pageof 6

Showing results (31-40 of 54) with videos related to

Sort By:
Pageof 6
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|August 23, 2014
N-terminal modifications improve the receptor affinity and pharmacokinetics of radiolabeled peptidic gastrin-releasing peptide receptor antagonists: examples of 68Ga- and 64Cu-labeled peptides for PET imagingEleni Gourni, Rosalba Mansi, Mazen Jamous, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 15, 2011
Bombesin antagonist-based radioligands for translational nuclear imaging of gastrin-releasing peptide receptor-positive tumorsKeelara Abiraj, Rosalba Mansi, Maria-Luisa Tamma, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 13, 2009
Evaluation of a 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-conjugated bombesin-based radioantagonist for the labeling with single-photon emission computed tomography, positron emission tomography, and therapeutic radionuclidesRosalba Mansi, Xuejuan Wang, Flavio Forrer, et al.
Journal of Medicinal Chemistry|December 5, 2014
Evaluation of three different families of bombesin receptor radioantagonists for targeted imaging and therapy of gastrin releasing peptide receptor (GRP-R) positive tumorsRosalba Mansi, Keelara Abiraj, Xuejuan Wang, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|April 30, 2016
Approaches to Improve the Pharmacokinetics of Radiolabeled Glucagon-Like Peptide-1 Receptor Ligands Using Antagonistic TracersSvetlana N Rylova, Beatrice Waser, Luigi Del Pozzo, et al.
EJNMMI Research|February 22, 2016
Pre-clinical evaluation of eight DOTA coupled gastrin-releasing peptide receptor (GRP-R) ligands for in vivo targeting of receptor-expressing tumorsAntonella Accardo, Filippo Galli, Rosalba Mansi, et al.
EJNMMI Radiopharmacy and Chemistry|August 21, 2025
Enhanced contrast in FAP-targeting PET imaging with <sup>61</sup>Cu-labeled FAP inhibitors: development and preclinical evaluation of novel [<sup>61</sup>Cu]Cu-Kalios PET radioligandsJacopo Millul, Tais Basaco Bernabeu, Raghuvir H Gaonkar, et al.
Bioconjugate Chemistry|May 15, 2015
Stereochemistry of amino acid spacers determines the pharmacokinetics of (111)In-DOTA-minigastrin analogues for targeting the CCK2/gastrin receptorPetra Kolenc Peitl, MariaLuisa Tamma, Marko Kroselj, et al.
EJNMMI Research|February 18, 2014
Synergism of peptide receptor-targeted Auger electron radiation therapy with anti-angiogenic compounds in a mouse model of neuroendocrine tumorsAndreas Wicki, Damian Wild, Vincent Prêtre, et al.
Journal of Translational Medicine|September 7, 2023
CUDC-907, a dual PI3K/histone deacetylase inhibitor, increases meta-iodobenzylguanidine uptake (<sup>123/131</sup>I-mIBG) in vitro and in vivo: a promising candidate for advancing theranostics in neuroendocrine tumorsJoana Grand-Guillaume, Rosalba Mansi, Raghuvir H Gaonkar, et al.
Pageof 6